CDK4 and neoplasm: To explore possible benefits of sequential therapies, we used syngeneic subcutaneous and orthotopic HNSCC tumor model mice to test whether brief CDK4/6i pretreatment could improve subsequent response to anti‐PD‐1, with or without continued CDK4/6i dosing.